Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Münster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001.

× No keyword cloud information.

10 in total

Review 1. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.

Authors: Xiangyi Lu; Li Xiao; Luan Wang; Douglas M Ruden
Journal: Biochem Pharmacol Date: 2011-11-22 Impact factor: 5.858

2. Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates.

Authors: Yuji Kasuya; Zheng-Rong Lu; Pavla Kopecková; S Esmail Tabibi; Jindrich Kopecek
Journal: Pharm Res Date: 2002-02 Impact factor: 4.200

3. Tuning polypeptide-based micellar carrier for efficient combination therapy of ErbB2-positive breast cancer.

Authors: Kruti S Soni; Fan Lei; Swapnil S Desale; Luis A Marky; Samuel M Cohen; Tatiana K Bronich
Journal: J Control Release Date: 2017-09-11 Impact factor: 9.776

4. A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.

Authors: Gopa Iyer; Michael J Morris; Dana Rathkopf; Susan F Slovin; Macaulay Steers; Steven M Larson; Lawrence H Schwartz; Tracy Curley; Anthony DeLaCruz; Qing Ye; Glenn Heller; Merrill J Egorin; S Percy Ivy; Neal Rosen; Howard I Scher; David B Solit
Journal: Cancer Chemother Pharmacol Date: 2011-11-29 Impact factor: 3.333

Review 5. Update on Hsp90 inhibitors in clinical trial.

Authors: Y S Kim; S V Alarcon; S Lee; M-J Lee; G Giaccone; L Neckers; J B Trepel
Journal: Curr Top Med Chem Date: 2009 Impact factor: 3.295

6. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors.

Authors: David Hong; Rabih Said; Gerald Falchook; Aung Naing; Stacy Moulder; Apostolia-Maria Tsimberidou; Gerald Galluppi; Naveen Dakappagari; Chris Storgard; Razelle Kurzrock; Lee S Rosen
Journal: Clin Cancer Res Date: 2013-07-19 Impact factor: 12.531

Review 1. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.

2. Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates.

3. Tuning polypeptide-based micellar carrier for efficient combination therapy of ErbB2-positive breast cancer.

4. A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.

Review 5. Update on Hsp90 inhibitors in clinical trial.

6. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors.

7. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.

8. Significance of expression of heat shock protein90alpha in human gastric cancer.

9. Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation.

Review 10. Protein folding, protein homeostasis, and cancer.